ExeGi Pharma

19 articles about ExeGi Pharma

• ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346

  12/8/2023

  ExeGi Pharma has announced the first patient enrollment in its landmark PROF Trial.

• Visbiome® GI Care High Potency Capsules Now Certified by the Clean Label Project®

  11/9/2023

  ExeGi Pharma LLC, a leader in digestive health solutions, is proud to announce that its flagship product, Visbiome GI Care Probiotic Capsules, has achieved the prestigious Clean Label Project® Certification and Clean Label Project Pesticide Free Certification.

• ExeGi Pharma Announces Clearance of Investigational New Drug (IND) Application for EXE- 46 a Live Biotherapeutic Biologic Drug

  1/26/2023

  ExeGi Pharma LLC, a leader in the development of live biotherapeutic drugs and probiotics, announced today that the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346.

• New Study Suggests Visbiome Vet May Support Gastrointestinal Health in Dogs Undergoing Chemotherapy Treatment

  5/20/2021

  A recent study published in Veterinary Record Open suggests that Visbiome® Vet probiotic may help mitigate occasional gastrointestinal concerns in dogs undergoing chemotherapy treatment for lymphoma.

• Appeals Court Upholds False Advertising Verdict Against Sellers of VSL#3® Probiotic

  2/19/2021

  ExeGi Pharma LLC, a company focused on developing live biotherapeutic drugs and probiotics, announced that the United State Court of Appeals for the Fourth Circuit has upheld a prior $15 million jury verdict in which the sellers of the VSL#3® probiotic were found liable for false advertising.

• New Study Finds Visbiome High Potency Probiotic May Benefit Some Autistic Children

  10/15/2020

  A new study published in the peer-reviewed journal Frontiers in Psychiatry finds the high-potency De Simone Formulation probiotic medical food may positively impact behavioral profiles in some children with Autism Spectrum Disorder.

• 

  Clinical Catch-Up: July 13-17

  7/20/2020

  It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.

• First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes

  7/13/2020

  Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients

• 

  Biopharma Update on the Novel Coronavirus: July 13

  7/13/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.

• ExeGi Pharma Probiotics to be Studied in Multiple Sclerosis Patients

  9/9/2019

  The study will explore the effects of probiotics on the gut microbiota and immune systems of people living with MS.

• ExeGi Wins Court Ruling Against VSL#3®*, Permanent Injunction Blocks False Advertising To Doctors, Consumers

  6/25/2019

  Federal district court finds in favor of ExeGi and probiotic inventor, prohibits VSL#3 sellers from citing studies on original formulation

• Trans-Atlantic study finds promising results with Visbiome Vet, a high potency probiotic, in dogs with severe form of acute diarrhea

  12/12/2018

  ExeGi Pharma announced positive results from a recent study conducted at the Clinic of Small Animal Medicine at Ludwig Maximilian University (LMU) in Munich, Germany and the Department of Small Animal Clinical Sciences at Texas A&M University.

• Visbiome® Vet probiotic to be the subject of two new clinical trials in domestic dogs

  9/12/2018

  ExeGi Pharma is pleased to announce two new clinical partnerships with the College of Veterinary Medicine at the University of Georgia and the University of Tennessee to study the Visbiome Vet probiotic in domestic dogs.

• ExeGi Pharma Launches High Potency Veterinary Probiotic To Help Manage GI Tract Illnesses In Dogs

  3/13/2018

  Clinical studies show probiotic used to manage human GI disorders can help support bowel and gut health in dogs

• ExeGi Pharma Release: Health Canada Approves Visbiome Probiotic For Irritable Bowel Syndrome

  9/27/2017

• ExeGi Pharma Release: Multi-Strain Probiotic May Play A Role In The Recovery Of Critical Gastrointestinal Functions In HIV-1-Positive Patients

  5/2/2017

• ExeGi Pharma Release: High Concentration Probiotic May Reduce Gastrointestinal And Neurological Inflammation In HIV Patients

  10/21/2016

• ExeGi Pharma Launches Visbiome Probiotic

  2/1/2016

• ExeGi Pharma Secures License For Well-Studied Probiotic

  5/18/2015